> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Proposes 2 Drug Communication Studies
- URL: https://www.fdaweb.com/fda-proposes-2-drug-communication-studies/
- Published: 2018-10-17T12:00:00.000Z
- Updated: 2026-09-15T00:38:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142608

FDA is seeking comments on two proposed studies involving direct-to-consumer and professional drug communications. In the first [study](https://www.gpo.gov/fdsys/pkg/FR-2018-10-17/pdf/2018-22570.pdf?ref=fdaweb.com), the CDER Office of Prescription Drug Promotion (OPDP) will examine the presence, wording, and prominence of a disclosure communicating information related to a drug’s accelerated approval in direct-to-consumer promotional materials. A *Federal Register* notice describes how the research will be conducted.

In the second [study](https://www.gpo.gov/fdsys/pkg/FR-2018-10-17/pdf/2018-22569.pdf?ref=fdaweb.com), the OPDP will examine important public health issues in professionally directed prescription drug print promotion. The research will look at how physician perception of professional prescription drug communications is influenced by variations in information context, methodologic rigor of the underlying clinical study, and time pressure.